LVTX — LAVA Therapeutics NV Share News
0.000.00%
Last trade - 00:00- $45.77m
- -$3.89m
- $11.98m
Brief: Lava Therapeutics Presents Preclinical Data On Its Gammabody™ T Cell Engager Platform At 21St Annual Peptalk Conference
Brief: Lava Therapeutics Provides Business Update And Reports Third Quarter Financial Results
Brief: LAVA Therapeutics NV Receives FDA Orphan Drug Designation For LAVA-051
NASDAQ RESUMED AT 11:54 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:49 AM
Lava Therapeutics Nv Reports Results For The Quarter Ended In June: Earnings Summary
Brief: Lava Therapeutics Reports Cash Balance of $151 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:46 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:21 AM
Brief: LAVA Therapeutics Announces Treatment Of First Patient In Phase 1/2A Clinical Trial Of Lava-051 For Multiple Hematological Malignancies
Brief: LAVA Therapeutics Announces Treatment Of First Patient In Phase 1/2A Clinical Trial Of Lava-051 For Multiple Hematological Malignancies
Lava Therapeutics Nv Reports Results For The Quarter Ended In March: Earnings Summary
Brief: LAVA Therapeutics NV Q1 Loss Per Share EUR 10.19
Brief: Redmile Group Reports 11.1% Passive Stake In Lava Therapeutics NV
NASDAQ RESUMED AT 01:39 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:19 AM